Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis said the decision to terminate the sale of Sandoz US#39;s generic oral solids and dermatology businesses was taken after the companies did not get approval from the U.S. Federal Trade Commission within anticipated timelines.

from Moneycontrol Business News https://ift.tt/2X3yjLJ